A novel oral ketamine drug was well tolerated and associated with reduced depressive symptoms in treatment-resistant depression (TRD) without significant dissociative effects, findings from two ...
FMP374 is a dual-acting NMDA modulator aiming to overcome challenges with older NMDA antagonists. In preclinical TRD models, ...
Eli Lilly has struck a deal to buy AtaiBeckley for $2.8 billion upfront, continuing its takeover spree to move into a ...
A Helicopter Couple struggling with conflict over grandchild care appeared on Oh Eun Young's Report: Marriage Hell.
Axios on MSN
The new mental health treatment
A longtime party drug is finding a new role treating depression and PTSD for hundreds of Charlotteans. Why it matters: ...
Rachel Aviv’s essay collection, “You Won’t Get Free of It,” shows the breadth and complexity of matrilineal relationships.
In Rachel Aviv's new essay collection 'You Won't Get Free of It,' she explores childhood trauma, mental illness and the ...
Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular diseases, announces an expansion of ...
Oral prolonged-release ketamine formulation (KET01) demonstrates minimal dissociation and cardiovascular effects with early antidepressant ...
Santhera Pharmaceuticals (SIX: SANN) today announces an expansion of its exclusive distribution agreement with Biomedica for AGAMREE® (vamorolone), extending the partnership to include Georgia, ...
In a powerful Marie Claire podcast episode, Jess Denham opens up about surviving childhood abuse, living with DID, media ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results